On Thursday, Memorial Resource Development Corp (NASDAQ:MRD)’s shares inclined 0.22% to $18.25.
Memorial Resource Development declared that William J. (Bill) Scarff, President, and Andrew J. Cozby, Senior Vice President and Chief Financial Officer, are planned to present at the Johnson Rice Energy Conference in New Orleans, Louisiana on Monday, September 28, 2015 at 4:05 p.m. Central (5:05 p.m. Eastern).
Memorial Resource Development Corp. is an independent natural gas and oil company. The Company is focused on the acquisition, exploration and development of natural gas and oil properties. Its properties include Cotton Valley, Cotton Valley—Terryville Complex, Other North Louisiana and Rockies.
VIVUS, Inc. (NASDAQ:VVUS)’s shares gained 1.23% to $1.62.
VIVUS declared that its Board of Directors has determined that it expresses no opinion and remains neutral toward the unsolicited tender offer by IEH Biopharma LLC, a Delaware limited liability company and wholly-owned partner of Icahn Enterprises Holdings L.P. (together, the “Icahn Group”), to purchase any and all of VIVUS’s 4.50% Convertible Senior Notes due 2020.
The Company noted that its Board believes each noteholder should make their own decision as to whether to tender in connection with the Icahn Group’s unsolicited tender offer based on the noteholder’s particular circumstances. It further indicated that its Board believes the determination is a financial decision to be made by each noteholder based on the terms of the tender and the cash price being offered by the Icahn Group. Accordingly, the Board concluded that it would be appropriate to remain neutral as to whether the noteholders should or should not tender the notes.
The Board, however, strongly urges the Company’s noteholders to consider carefully all aspects of the Icahn Group’s offer before deciding for themselves whether to tender.
VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes.
At the end of Thursday’s trade, Yingli Green Energy Holding Co Ltd (ADR) (NYSE:YGE)‘s shares dipped -7.03% to $0.410.
Yingli Green Energy Holding declared that it recently signed several agreements with Qingdao New Energy Solutions Inc. (NESI), a leading provider of agricultural and industrial building-integrated photovoltaic (BIPV) and utility-scale solar solutions, for the supply of 130 megawatts (MW) of high quality solar panels. Yingli has begun to deliver the first 30 MW and anticipates to complete the delivery by the end of September 2015.
According to the terms of the companies’ supply agreements, Yingli will supply the remaining 100 MW of solar panels by the end of the second quarter of 2016. These panels will be used in utility-scale projects, industrial rooftop systems in addition to BIPV agricultural solutions, in Zhejiang, Inner Mongolia, Shandong and other provinces in China.
In total, Yingli will provide NESI with more than 500,000 multicrystalline YGE 60 Cell Series solar panels that are predictable to generate about 150,000 megawatt-hours (MWh) of clean energy per year once operational. The clean energy they produce will offset about 120,000 tons of carbon emissions annually.
Yingli Green Energy Holding Company Limited is a supplier of vertically integrated photovoltaic (PV) module. The Company’s products and services cover the entire PV industry value chain, ranging from crystalline polysilicon ingots and wafers, PV cells and PV modules to the manufacture of PV systems and the installation of PV systems.
Baxalta Inc (NYSE:BXLT), ended its Thursday’s trading session with -1.62% loss, and closed at $34.11.
Baxalta declared that it has presented an application to the U.S. Food and Drug Administration (FDA) for approval of an investigational 20 percent concentration immunoglobulin subcutaneous (IGSC, 20%) treatment for patients with primary immunodeficiencies (PI, a group of disorders in which part of the body’s immune system is missing or does not function properly).
The U.S. filing is based on positive results of a Phase 2/3 study of IGSC, 20% in North American patients at least two years old with PI. In the study, IGSC, 20% met the primary endpoint as measured by the rate of acute serious bacterial infections (ASBIs). A single ASBI was stated with IGSC 20 percent treatment, equating to 0.012 ASBI/patient-year (p<0.0001, contrast with the reference threshold of one ASBI/patient-year). The rate of all infections was 2.41/patient-year.
Nearly all infusions (99.8 percent) were accomplished without a reduction, interruption, or discontinuation for tolerability reasons and 84.9 percent of infusions were administered using ≤ 2 infusion sites. The rate of local adverse reactions (ARs) to IGSC, 20% was 0.022/ infusion. All (100 percent) of the local ARs were either mild (92.5 percent) or moderate (7.5 percent) in severity. The most common ARs were local adverse reactions, systemic adverse reactions counting headache, nausea, fatigue, diarrhea, and vomiting. The complete data will be presented at an forthcoming medical congress.
Baxalta Incorporated is a biopharmaceutical company. The Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions. The Company also focuses on disease areas, including oncology, as well as technology platforms, including gene therapy and biosimilars.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
